title: Cardiovascular risk assessment in oncological clinical trials: is there a role for centralized events adjudication?
authors.affiliation: Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA.
authors.forename: Muthiah
authors.initials: M
authors.lastname: Vaduganathan
authors.affiliation: Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
authors.forename: Vinay
authors.initials: V
authors.lastname: Prasad
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D066126:Cardiotoxicity; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000175:diagnosis* / Q000453:epidemiology*; D002986:Clinical Trials as Topic; D015897:Comorbidity; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology*; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents